Edition:
United States

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

6.65USD
24 Mar 2017
Change (% chg)

$0.05 (+0.76%)
Prev Close
$6.60
Open
$6.70
Day's High
$6.70
Day's Low
$6.55
Volume
15,834
Avg. Vol
36,276
52-wk High
$18.44
52-wk Low
$6.10

Latest Key Developments (Source: Significant Developments)

Applied Genetic Technologies quarterly revenue $10.9 million versus $12.2 million
Wednesday, 8 Feb 2017 04:10pm EST 

Applied Genetic Technologies Corp : Quarterly revenue $10.9 million versus $12.2 million . Applied Genetic Technologies says total revenue for three months ended Dec 31, 2016 was $10.9 million compared to $12.2 million during same period in 2015 .Qtrly earnings per share $ 0.11.  Full Article

Applied Genetic Technologies quarterly EPS $0.20
Tuesday, 8 Nov 2016 04:09pm EST 

Applied Genetic Technologies Corp : Qtrly earnings per share $0.20 .Quarterly revenue $11.8 million versus $11.1 million.  Full Article

Applied Genetic Technologies announces orphan medicinal product designation in European Union for gene therapy
Tuesday, 7 Jun 2016 07:00am EDT 

Applied Genetic Technologies Corp :Announces orphan medicinal product designation in European Union for gene therapy to treat x-linked retinitis pigmentosa.  Full Article

AGTC announces results for the quarter ended March 31
Monday, 9 May 2016 04:03pm EDT 

Applied Genetic Technologies Corp : Agtc announces financial results for the quarter ended march 31, 2016 .Quarterly revenue $12 million versus $284,000.  Full Article

Applied Genetic Technologies Corp files investigational new drug application for the treatment of achromatopsia caused by mutations in the cngb3 gene
Monday, 2 Nov 2015 07:01am EST 

Applied Genetic Technologies Corp:Files investigational new drug application for the treatment of achromatopsia caused by mutations in the cngb3 gene.Plans to initiate clinical study evaluating safety and efficacy of agtc's proprietary gene therapy at four sites in U.S.  Full Article

Applied Genetic Technologies Corp announces orphan drug designation in European Union for gene therapy to treat achromatopsia
Thursday, 22 Oct 2015 07:01am EDT 

Applied Genetic Technologies Corp:Announces orphan drug designation in European Union for gene therapy to treat achromatopsia.Orphan drug designation to investigational gene therapy product for treatment of achromatopsia caused by mutations in cnga3 gene.  Full Article

Biogen Inc and Applied Genetic Technologies Corp enter collaboration to develop gene therapies in ophthalmology
Thursday, 2 Jul 2015 07:00am EDT 

Biogen Inc and Applied Genetic Technologies Corp (AGTC):Enter collaboration to develop gene therapies in Ophthalmology.Says AGTC to receive $124 Mln upfront, with potential future milestone payments and royalties.Says collaboration will focus on the development of a portfolio of AGTC's therapeutic programs.Says upfront payment includes $30 million equity investment in AGTC at a price equal to $20.63 per share and some prepaid research and development expenditures.Says Biogen will be granted a license to the xl rs and xl rp programs.Will be granted option to license discovery programs for 3 additional indications at the time of clinical candidate selection.  Full Article

Applied Genetic Technologies Corp and 4D Molecular Therapeutics sign collaboration agreement for gene therapy vector discovery and product development
Monday, 20 Apr 2015 07:00am EDT 

Applied Genetic Technologies Corp:Says collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need.Says part of agreement, 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel vectors.Financial details were not disclosed.  Full Article

More From Around the Web

BRIEF-Applied Genetic Technologies quarterly revenue $10.9 million versus $12.2 million

* Applied Genetic Technologies says total revenue for three months ended Dec 31, 2016 was $10.9 million compared to $12.2 million during same period in 2015